Introduction: Suzhou Connect Biopharmaceutical Company ("Suzhou Connect") was founded in early 2012 by a team of returnee PhDs with successful experience in new drug development and domestic and foreign entrepreneurship in the pharmaceutical industry. The company is adjacent to Shanghai (Suzhou) Taicang Biomedical Industrial Park.
Suzhou Connect focuses on developing basic innovative drugs for the treatment of autoimmunity and tumors targeting G protein-coupled receptors ("GPCR"). The company has independently developed GPCR monoclonal antibody drug technology. , and strives to become a unique international leader in the development of GPCR monoclonal antibody drugs. We will further expand this technology platform and develop a series of related antibody drugs. At the same time, we will also actively introduce technologies and products with global patent development rights and use increasingly perfect biopharmaceutical R&D outsourcing CRO services to rapidly advance the preclinical development of each new drug development project. Research and apply to obtain clinical research (IND) approval from the US FDA and China SFDA, and then complete further industrial development independently or with large pharmaceutical companies and achieve final market promotion.
Suzhou Connect has the global rights to use several related drug development technologies and product patents, and has applied to the U.S. Patent Office for a global patent for independently developed GPCR monoclonal antibody technology. At present, Suzhou Connect is actively promoting the preclinical development and industrialization of new drug projects of Arena Pharmaceuticals in the United States. The drugs developed will be used to treat allergic rhinitis and allergic dermatitis.
Company address:
215400 China, Jiangsu Province, Taicang City, No. 3 Chaoyang East Road, 5th Floor, Xiangtang Development Building
Telephone/Fax: 0512 -53577866
Email: qchang@connectpharm.com
Company website: /
Legal representative: WUBIN PAN (Pan Wubin)
Date of establishment: 2012-05-02
Registered capital: RMB 41.288326
Region: Jiangsu Province
Unified social credit code: 9132058559556746XW
Business status: In business
Industry: Scientific research and technical services
Company type: Limited liability company (sole proprietorship of Taiwan, Hong Kong and Macao legal persons)
Staff size: 100-499 people
Company address: No. 6, Beijing West Road, Economic Development Zone, Taicang City
Business scope: engaged in the research and development of new biomedical products and their technology development, Technology exchange, technology introduction, technology promotion, technology transfer, technology services; bioengineering, biomedical engineering and biomedical technology consulting and services. (Projects that require approval according to law can only be carried out with approval from relevant departments)